Anti tumor compositions and methods of use

Details Anti tumor compositions and methods of use Anti tumor compositions and methods of use

2004-07-09

2008-11-11

Richter, Johann (Department: 1616)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Implant or insert

C424S417000, C424S418000, C424S450000, C424S493000, C424S630000, C424S646000, C514S499000, C514S502000

Reexamination Certificate

active

07449196

ABSTRACT:
An anti-cancer composition having biocompatible materials, which can selectively exploit chemical variations between normal cells and cancer cells to inhibit or prevent the proliferation of cancerous cells and methods of use.

REFERENCES:
patent: 2924551 (1960-02-01), Harwood et al.
patent: 4101669 (1978-07-01), Baude et al.
patent: 4177263 (1979-12-01), Rosenberg et al.
patent: 4193993 (1980-03-01), Hilditch
patent: 4569836 (1986-02-01), Gordon
patent: 4670429 (1987-06-01), Dombay et al.
patent: 4745129 (1988-05-01), Ikari et al.
patent: 4952607 (1990-08-01), Sorenson et al.
patent: 5124351 (1992-06-01), Rabinovitz et al.
patent: 5202353 (1993-04-01), Schroth et al.
patent: 5624668 (1997-04-01), Lawrence et al.
patent: 5632982 (1997-05-01), Sussman et al.
patent: 5635532 (1997-06-01), Samid
patent: 5876781 (1999-03-01), Lasdon et al.
patent: 6225489 (2001-05-01), Fost et al.
patent: 6235776 (2001-05-01), Pamukcu et al.
patent: 6248712 (2001-06-01), Dan.o slashed. et al.
patent: 6252058 (2001-06-01), Thompson
patent: 6258774 (2001-07-01), Stein et al.
patent: 6355268 (2002-03-01), Slater et al.
patent: 6465008 (2002-10-01), Slater et al.
patent: 6506405 (2003-01-01), Desai et al.
patent: 6534096 (2003-03-01), Shaw
patent: 6537988 (2003-03-01), Lee
patent: 6703050 (2004-03-01), Brewer et al.
patent: 6706759 (2004-03-01), Kennedy
patent: 6747148 (2004-06-01), Peyman et al.
patent: 2001/0051183 (2001-12-01), Martin
patent: 2002/0172711 (2002-11-01), Martin
patent: 2002/0198166 (2002-12-01), Rothman et al.
patent: 2003/0083367 (2003-05-01), Murray et al.
patent: 2003/0158249 (2003-08-01), Chi et al.
patent: 2003/0187039 (2003-10-01), Favreau et al.
patent: 2003/0195161 (2003-10-01), Bissery
patent: 2003/0195214 (2003-10-01), Camden et al.
patent: 2003/0198235 (2003-10-01), Weldon et al.
patent: 2003/0198638 (2003-10-01), Watkins
patent: 2003/0199469 (2003-10-01), Schwartz et al.
patent: 2004/0204385 (2004-10-01), Leech
patent: 2004/0224005 (2004-11-01), Gabbay
MedlinePlus Medical Encyclopedia: Cancer [online] Jul. 14, 2006 retrieved Oct. 18, 2006 retrieved from the internet http://www.nlm.nih.gov/medlineplus/ency/article/000583.htm pp. 1-3.
MedlinePlus Medical Encyclopedia: Multiple Myeloma [online] Aug. 3, 2004 retrieved Oct. 18, 2006 retrieved from the internet http://www.nlm.nih.gov/medlineplus/ency/article/001289.htm pp. 1-4.
Tabata et al. Journal of Controlled Release 1999, 59, 187-196.
Szabo USA Today Killer Cancer Genes ID'd Sep. 7, 2006, pp. 1-2.
Pan et al. Cancer Research 2002, 62, 4854-4859.
Lowndes et al. Oncology Research 2004, 14, 529-539.
Google internet search, [online] retrieved from the internet on Sep. 25, 2007, retrieved from www.google.com 3 pages.
Alza's Stealth® Liposomal Technology; Current Therapies and Future Opportunities, Alza Corporation, Delivery Times Issues and Opinions, vol. II, Issue 1, 1-11, 2002.
Consumers Guide to Cancer Drugs, The American Cancer Society, Jones and Bartlett Publishers (previously supplied as a book) (2000) pp. 1-448.
Cancer Facts and Figures 2003, The American Cancer Society report, p. 4 (2003).
It's Not About the Bike, Armstrong, Lance, Berkley Publishing (previously supplied as a book) (2000).
Copper ion-dependent damage to the base pairs in DNA in the presence of hydrogen peroxide, Aruoma, Biochem. Jour., 273: 601-4 (1991) 1 page abstract.
Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients with Chemotherapy-Related Anemia: A Multicenter. Open-Label, Randomized Trial, Auerbach, J. of Clin. Oncology 227-1301-1307 (2004).
Circulation and Biodistribution Profiles of Long-Circulating PEG Liposomes of Various Sizes in Rabbits, Awasthi, Int. Journal of Pharmaceutics 253 (2003) 121-122.
Cancer Chemotherapy Handbook, Baquiran, Lippincott, p. 85 (2001) p. 85.
An Indistinct Balance: The Safety and Efficacy of Parenteral Iron Therapy, Besarab, Journal of American Society of Nephrology, vol. 10, No. 9, 23 pages (Sep. 1999).
Angiogenesis and Cancer Control: From Concept to Therapeutic Trial, Brem, Cancer Control Jour., 6 (5):436-458 (1999).
Phase II Trial of Copper Depletion as Angiosuppresive Treatment in Newly Diagnosed Gliobastoma Multiforme: Final Report, Brem, et al., Journal of Clinical Oncology vol. 22, No. 14S, (2004) 1 page abstract.
“Control of Copper in Wilson's Disease and Diseases of Neovascularization, such as Cancer”,Handbook of Copper Pharmacology and Toxicology, Brewer, Humana Press, Chap. 27, (2002).
Copper Control as an Antiangiogenic Anticancer Therapy: Lessons from Treating Wilson's Disease, Brewer, Exp. Bio. and Med., 226(7):665-673 (2001).
Treatment of Metastatic Cancer with Tetrathiomolybdate, an Anticopper, Antiangiogenesis Agent: Phase I Study, Brewer, et al., Clin. Cancer Res., 6:1-10 (2000).
Applied and Envir. Microbio., Clarke et al., May 1987 pp. 917-922.
Gallium in Cancer Treatment., Collery, et al., Crit. Rev. in Oncology/Hematology 42:283-296 (2002).
Inhibition of the Growth of Squamous Cell Carcinoma by Tetrathiomolybdate-Induced Copper Supression in a Murine Model, Cox, Merajver, Yoo, Dick, Brewer, Lee and Teknos, Arch Otolaryngol Head Neck Surg. 2003; 129:781-785 (2003) 1 page abstract.
Structure of an iron-dextran complex, Cox, J. of Pharma & Pharmac, 24:513-517 (1972).
Physicians' Cancer Chemotherapy Drug Manual, 2003, Chu & Devita, Jones and Bartlett Publishers, (2003) pp. 12-20.
Glycolysis and GLUT1 in Breast Tumors: Markers of Response to Hormonal Therapy, Degani, The American Society of Clinical Oncology, Intn'l J. of Cancer 107:177-182 (Nov. 2003),2 page summary in asco.org.
Cancer in Metals and Metal Compounds: Part I—Carcinogenesis, Desoize, B., Editor, Critical Reviews in Oncology/Hematology, 42:1-3 (2002).
Cancer and Metals and Metal Compounds, Part II—Cancer Treatment, Desoize, B. Editor, Crit. Rev. In Oncology/Hematology, 42:213-215 (2002).
(Iron Dextran Injection), USP, DEXFERRUM® American Regent, Inc., Package insert, (2004).
Synthesis, cytotoxicity, and antitumor activity of copper(II)and Iron(III)complexes of(4)N-azabicyclo[3.1.2] nonane thiosemicarbazones derived from acyl diazines, Easmon, J. Med. Chem, Jun. 2001, 44(13):2164-71, 2 page abstract.
Hepatitis C Virus Infection and Non-Hodgkin Lymphoma: Results of the NCI-seer Multi-center Case-control Study, Engels et al., Int. Journal of Cancer, vol. 111, Issue 1, 76-80 (2004) 3 page abstract.
Advances in FDG PET Probes in Surgical Oncology, Essner, et al., Cancer Jour. 8:100-108 (2002).
The Role of Oxidative Stress in Mechanisms of Metal-Induced Carcinogenesis, Galaris, et al., Critical Reviews In Oncology/Hematology, 42:93-103 (2002).
The glycolysis phenotype in carcinogenesis and tumor invasion: insights through mathematical models, Gatenby and Gawlinski, Cancer Res., 63(14):3847-54 (Jul. 2003).
Why Do Cancers Have High Aerobio Glycolysis?, Gatenby and Gillies, Nature Reviews Cancer, 4 (Nov. 2004).
Novel Therapy for Liver Cancer: Direct Intraarterial Injection of a Potent Inhibitor of ATP Production, Geschwind, Ko, Torbenson, Magee and Pedersen, Cancer Research 62, 3909-3913, Jul. 15, 2002.
Cancer-Treating Cancer with Insulin Potentiation Therapy, Hauser & Hauser, Boulah Land Press, (2001), pp. 1-414., (previously supplied as a book).
Characteristics of Iron Dextran Utilization in Man, Henderson & Hillman, Blood, 34(3):357-375 (1969).
An Innovative Drug Delivery Technology, Johnson, Magnetics Business & Technology Magazine, (2002).
Cancer Combat, King, (previously supplied as book).
Journal D'Agriculture Pratique, pp. 698-700, 728-729, and 765-766 (1887) (No translation).
Paclitaxel analog kills more cancer cells than natural product, Kingston, David, et al., American Chemical Society, Mar. 28, 2004.
The Iron Metabolism of Neoplastic Cells: alterations that facilitate proliferation?, Kwok, et al., Crit. Rev. In Oncology/Hematology 42:65-78 (2002).
Comparative Analysis of Copper and Iron Metabolism in Photosynthetic Eukaryotes vs. Yeast and Mammals, LaFontaine; Massaro,Handbook of Copper Pharmacology and Toxicology, Chapter 30,

Affiliated with

Also associated with

Rating

Anti tumor compositions and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti tumor compositions and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti tumor compositions and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4031533